Rani Therapeutics Holdings financials
$0.8003+3.13%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.7M | $1.7M | $1.5M | $0.00 | $0.00 | $172.0K | $1.0M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $1.7M | $1.7M | $1.5M | $0.00 | $0.00 | $172.0K | $1.0M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | 100.0% | 100.0% | 100.0% | — | — | 100.0% | 100.0% | — | — | — | — | — |
| Operating income | -$8.8M | -$8.3M | -$8.5M | -$7.3M | -$10.5M | -$12.0M | -$15.0M | -$11.8M | -$12.5M | -$14.0M | -$13.4M | -$17.9M |
| Net income | -$7.4M | -$7.0M | -$10.3M | -$5.4M | -$6.7M | -$7.3M | -$8.9M | -$6.8M | -$6.8M | -$7.5M | -$7.1M | -$9.2M |
| Net margin | −432.7% | −411.8% | −705.3% | — | — | −4223.3% | −870.3% | — | — | — | — | — |
| Diluted EPS | $-0.04 | $-0.04 | $-0.07 | $-0.12 | $-0.18 | $-0.22 | $-0.27 | $-0.24 | $-0.26 | $-0.29 | $-0.27 | $-0.36 |
| EBITDA | -$8.7M | -$8.2M | -$8.3M | -$7.0M | -$10.3M | -$11.8M | -$11.0M | -$11.5M | -$12.3M | -$13.8M | -$13.2M | -$17.6M |
| Operating cash flow | -$9.0M | -$6.5M | $294.0K | -$5.1M | -$5.8M | -$8.1M | -$8.7M | -$8.4M | -$9.0M | -$9.4M | -$12.5M | -$14.3M |
| Free cash flow | -$9.1M | -$6.5M | $294.0K | -$5.1M | -$5.8M | -$8.2M | -$8.7M | -$8.5M | -$9.1M | -$9.4M | -$12.6M | -$14.8M |
| Diluted shares | 187.2M | 180.0M | 148.1M | 46.4M | 36.5M | 33.4M | 32.7M | 28.8M | 26.3M | 26.0M | 25.9M | 25.6M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $4.9M | $9.6M | $18.6M | $4.1M | $10.2M | $10.1M |
| Short-term investments | $48.5M | $33.8M | $31.1M | $0.00 | $0.00 | $5.7M |
| Total debt | $0.00 | $0.00 | $0.00 | $13.5M | $17.2M | $20.9M |
| Total assets | $60.8M | $51.9M | $58.6M | $10.1M | $16.9M | $24.1M |
| Total liabilities | $12.9M | $16.3M | $17.1M | $22.1M | $26.1M | $29.5M |
| Shareholders' equity | $48.0M | $35.5M | $41.5M | -$12.0M | -$9.2M | -$5.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology